Standard 38130

Name
CLSI M44-A2 Vol. 29 No. 17 Replaces M44-A Vol. 24 No. 15
Designation
M44-A2 Vol. 29 No. 17 Replaces M44-A Vol. 24 No. 15
Organization
CLSI
Recognition number
7-215
Recognition date
2019-01-14
Scope
This standard provides approved zone interpretive criteria (breakpoints) for Candida species for caspofungin, fluconazole, and voriconazole after 20 to 24 hours incubation, as well as quality control parameters for caspofungin, fluconazole, posaconazole, and voriconazole. There are currently more than 10 systemically active antifungal agents, and it is expected that this document will further encourage the development of disk diffusion testing for at least some of these additional agents and genera.
Rationale
This standard is relevant to medical devices and is recognized on its scientific and technical merit and/or because it supports existing regulatory policies.